

# STN Columbus

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
 NEWS 2 "Ask CAS" for self-help around the clock  
 NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
 STN Express with Discover!  
 NEWS 4 OCT 28 KOREAPAT now available on STN  
 NEWS 5 NOV 30 PHAR reloaded with additional data  
 NEWS 6 DEC 01 LISA now available on STN  
 NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004  
 NEWS 8 DEC 15 MEDLINE update schedule for December 2004  
 NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness  
 alerts (SDIs) affected  
 NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness  
 alerts (SDIs) affected  
 NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness  
 alerts (SDIs) affected  
 NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness  
 alerts (SDIs) affected  
 NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB  
 NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN  
 NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED  
 NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and  
 February 2005  
 NEWS 17 JAN 26 CA/CAPLUS - Expanded patent coverage to include the Russian  
 Agency for Patents and Trademarks (ROSPATENT)  
  
 NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT  
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
 AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005  
  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:37:18 ON 09 FEB 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'REGISTRY' ENTERED AT 16:39:37 ON 09 FEB 2005

STN Columbus

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4  
DICTIONARY FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> fil capl
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.43          1.27
```

FILE 'CAPLUS' ENTERED AT 16:39:50 ON 09 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 9 Feb 2005 VOL 142 ISS 7  
FILE LAST UPDATED: 8 Feb 2005 (20050208/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

```
=> s pde 4
    4515 PDE
    794 PDES
    4813 PDE
        (PDE OR PDES)
    5047744 4
L1      210 PDE 4
        (PDE(W)4)
```

```
=> s macular or retinopathy
```

## STN Columbus

1995 MACULAR  
 5929 RETINOPATHY  
 181 RETINOPATHIES  
 6004 RETINOPATHY  
 (RETINOPATHY OR RETINOPATHIES)

L2 7455 MACULAR OR RETINOPATHY

=> s l1 and l2

L3 2 L1 AND L2

=> d tot

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2004:453020 CAPLUS

DN 141:12309

TI Compositions comprising (+)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydroisoindol-2-yl)propionamide

IN Muller, George W.; Chen, Roger Shen-chu

PA Celgene Corporation, USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045597	A1	20040603	WO 2003-US36740	20031117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-427379P	P	20021118		

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2003:950880 CAPLUS

DN 140:8834

TI Topical pharmaceutical compositions containing a **PDE 4** inhibitor

IN Bolle, Christina; Linder, Rudolf

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003099334	A1	20031204	WO 2003-EP5524	20030527
	W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,				

## STN Columbus

SI, SK, TR

PRAI DE 2002-10223828 A 20020528  
 EP 2002-11830 A 20020528  
 DE 2003-10311613 A 20030314

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; s wo2001034606/pn

L4 2 WO2001034606/PN  
 (WO2001034606/PN)

=&gt; d

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2003:1001604 CAPLUS

DN 140:42030

TI Preparation of isoindolinediones as angiogenesis inhibitors.

IN Man, Hon-wah; Muller, George W.

PA Celgene Corporation, USA

SO U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 590,344.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6667316	B1	20031223	US 2000-708199	20001108
	CA 2392081	AA	20010517	CA 2000-2392081	20001109
	WO 2001034606	A1	20010517	WO 2000-US30770	20001109 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1228071	A1	20020807	EP 2000-977095	20001109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 519459	A	20031128	NZ 2000-519459	20001109
	JP 2004500346	T2	20040108	JP 2001-536553	20001109
	NO 2002002223	A	20020708	NO 2002-2223	20020508
	FI 2002000892	A	20020510	FI 2002-892	20020510
	US 2004147588	A1	20040729	US 2003-685942	20031014
PRAI	US 1999-165168P	P	19991112		
	US 2000-590344	A2	20000608		
	US 2000-708199	A	20001108		
	WO 2000-US30770	W	20001109		

OS MARPAT 140:42030

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d 2

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

## STN Columbus

## Full Text

AN 2001:359998 CAPLUS  
 DN 134:366799  
 TI Preparation of isoindolinones for treatment of phosphodiesterase- and  
 TNF $\alpha$ -mediated diseases  
 IN Man, Hon-Wah; Muller, George  
 PA Celgene Corporation, USA  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034606	A1	20010517	WO 2000-US30770	20001109 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6667316	B1	20031223	US 2000-708199	20001108
	CA 2392081	AA	20010517	CA 2000-2392081	20001109
	EP 1228071	A1	20020807	EP 2000-977095	20001109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 519459	A	20031128	NZ 2000-519459	20001109
	JP 2004500346	T2	20040108	JP 2001-536553	20001109
	NO 2002002223	A	20020708	NO 2002-2223	20020508
	FI 2002000892	A	20020510	FI 2002-892	20020510
PRAI	US 1999-165168P	P	19991112		
	US 2000-590344	A	20000608		
	US 2000-708199	A	20001108		
	WO 2000-US30770	W	20001109		

OS MARPAT 134:366799

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.10	17.37

FILE 'REGISTRY' ENTERED AT 16:43:41 ON 09 FEB 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4  
 DICTIONARY FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

# STN Columbus

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> s v-11294A
      208119 V
          1 11294A
L5      1 V-11294A
          (V(W) 11294A)
```

=> d

```
L5  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN  162278-09-3  REGISTRY
CN  3H-Purin-6-amine, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]-N-ethyl-8-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN  V 11294A
DR  328248-66-4
MF  C23 H31 N5 O2 . Cl H
SR  CA
LC  STN Files:  BIOSIS, CA, CAPLUS, CASREACT, EMBASE, PROUSDDR, SYNTHLINE,
      TOXCENTER, USPATFULL
DT.CA  Caplus document type:  Journal; Patent
RL.P  Roles from patents:  BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); USES (Uses)
CRN  (162278-10-6)
```



# HCl

25 REFERENCES IN FILE CA (1907 TO DATE)  
25 REFERENCES IN FILE CAPLUS (1907 TO DATE)

STN Columbus

=> s d-4418

6889239 D

1081 4418

L6

1 D-4418

(D(W)4418)

=> d

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 257892-34-5 REGISTRY

CN 5-Quinolinecarboxamide, N-(2,5-dichloro-3-pyridinyl)-8-methoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN D 4418

FS 3D CONCORD

DR 199871-60-8

MF C16 H11 Cl2 N3 O2


SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1907 TO DATE)

16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s brl-61063

385 BRL

4 BRLS

389 BRL

(BRL OR BRLS)

31 61063

L7

1 BRL-61063

(BRL(W)61063)

=> d

STN Columbus


L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 132210-43-6 REGISTRY  
 CN 1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- (9CI)  
 (CA INDEX NAME)

OTHER NAMES:

CN 8-Amino-1,3-bis(cyclopropylmethyl)xanthine  
 CN BRL 61063  
 CN Cipamfylline  
 FS 3D CONCORD  
 MF C13 H17 N5 O2  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, BIOSIS, CA, CANCERLIT, CAPLUS,  
 CASREACT, DDFU, DRUGU, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, PHAR,  
 PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL

Other Sources: WHO

DT.CA Caplus document type: Journal; Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP  
 (Properties); RACT (Reactant or reagent); USES (Uses)  
 RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP  
 (Properties); USES (Uses)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

44 REFERENCES IN FILE CA (1907 TO DATE)  
 44 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s sb-207499  
 37906 SB  
 35 SBS  
 37938 SB  
 (SB OR SBS)  
 8 207499  
 L8 1 SB-207499  
 (SB(W) 207499)


=> d

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 153259-65-5 REGISTRY  
 CN Cyclohexanecarboxylic acid, 4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-  
 , cis- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Ariflo

STN Columbus

CN Cilomilast  
 CN cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid  
 CN cis-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-4-cyanocyclohexane-1-carboxylic acid  
 CN **SB 207499**  
 FS STEREOSEARCH  
 MF C20 H25 N O4  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, PHAR, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 DT.CA Caplus document type: Conference; Journal; Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)  
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

140 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 142 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel rn name 15  
 E1 THROUGH E2 ASSIGNED

=> sel rn name 16  
 E3 THROUGH E4 ASSIGNED

=> sel rn name 17  
 E5 THROUGH E8 ASSIGNED

=> sel rn name 18  
 E9 THROUGH E14 ASSIGNED

STN Columbus

=> fil medl hcapl biosis uspatf wpids

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

47.01

64.38

FILE 'MEDLINE' ENTERED AT 16:45:25 ON 09 FEB 2005

FILE 'HCAPLUS' ENTERED AT 16:45:25 ON 09 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:45:25 ON 09 FEB 2005

Copyright (c) 2005 The Thomson Corporation.

FILE 'USPATFULL' ENTERED AT 16:45:25 ON 09 FEB 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:45:25 ON 09 FEB 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s e1-2; s e3-4; s e5-8; s e9-14

L9 125 ("V 11294A"/BI OR 162278-09-3/BI)

L10 106 ("D 4418"/BI OR 257892-34-5/BI)

4 FILES SEARCHED...

L11 182 ("BRL 61063"/BI OR CIPAMFYLLINE/BI OR 132210-43-6/BI OR "8-AMINO  
-1,3-BIS(CYCLOPROPYLMETHYL) XANTHINE"/BI)

2 FILES SEARCHED...

4 FILES SEARCHED...

L12 603 (ARIFLO/BI OR CILOMILAST/BI OR "CIS-4-(3-(CYCLOPENTYLOXY)-4-METH  
OXYPHENYL)-4-CYANOCYCLOHEXANE-1-CARBOXYLIC ACID"/BI OR "CIS-4-CY  
ANO-4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL) CYCLOHEXANECARBOXYLIC  
ACID"/BI OR "SB 207499"/BI OR 153259-65-5/BI)

=> s macular degenerat? or retinopathy

L13 72967 MACULAR DEGENERAT? OR RETINOPATHY

=> s l12 and l13

L14 24 L12 AND L13

=> dup rem l14

PROCESSING COMPLETED FOR L14

L15 24 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib abs 20-24

L15 ANSWER 20 OF 24 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

Full Text

ACCESSION NUMBER: 2004-594021 [57] WPIDS

DOC. NO. CPI: C2004-216075

TITLE: Use of phosphodiesterase-IV along with tumor necrosis  
factor-alpha for treatment/prophylaxis of e.g. pulmonary  
inflammatory disorders, pulmonary hypertension and  
asthma.

## STN Columbus

DERWENT CLASS: B02 B03  
 INVENTOR(S): WARNER, J M  
 PATENT ASSIGNEE(S): (PHAA) PHARMACIA CORP  
 COUNTRY COUNT: 108  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004067006	A1	20040812	(200457)*	EN	66
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE					
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE					
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG					
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ					
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG					
US UZ VC VN YU ZA ZM ZW					

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004067006	A1	WO 2004-IB616	20040123

PRIORITY APPLN. INFO: US 2003-442881P 20030127

AN 2004-594021 [57] WPIDS

AB WO2004067006 A UPAB: 20040907

NOVELTY - Treatment or prophylaxis of a phosphodiesterase-IV (PDE-IV) or a tumor necrosis factor- alpha (TNF- alpha ) related condition comprises administration of a PDE IV inhibitor (A) together with a TNF- alpha antagonist (B).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for  
 (1) a composition comprising (A) and a TNF-alpha antagonist (B) and a pharmaceutically acceptable excipient; and

(2) a kit for the treatment or prophylaxis of a PDE IV or a TNF-alpha related condition comprising a dosage form comprising (A) and a dosage form comprising (B).

ACTIVITY - Antiinflammatory; Respiratory-Gen.; Hypotensive; Antiasthmatic; Antiallergic; Antiarthritic; Osteopathic; Ophthalmological; Antidiabetic; Antiangiogenic; Antirheumatic; Neuroprotective.

MECHANISM OF ACTION - Phosphodiesterase-IV (PDE IV) inhibitor; TNF-alpha antagonist. Test details are described for TNF- alpha antagonistic activity but no results given.

USE - (A) along with (B) is useful in the treatment of PDE-IV or TNF-alpha related conditions (claimed) such as inflammatory disorders e.g. pulmonary inflammatory disorders, pulmonary hypertension, asthma, exercise induced asthma, pollution induced asthma, allergy induced asthma, chronic obstructive pulmonary disorder (COPD), osteoarthritis, adult respiratory distress syndrome, infant respiratory distress syndrome, retinitis, uveitis, glaucoma, **retinopathy**, diabetic angiopathy, edema formation, arthritis, rheumatoid arthritis and multiple sclerosis.  
 Dwg.0/0

L15 ANSWER 21 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2003:306096 USPATFULL

TITLE: Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

INVENTOR(S): Graham, Charles H., Kingston, CANADA  
 Postovit, Lynne-Marie, Kingston, CANADA

## STN Columbus

PATENT ASSIGNEE(S) : Adams, Michael A., Kingston, CANADA  
Heaton, Jeremy P.W., Gananoque, CANADA  
Queens University at Kingston, Kingston, CANADA  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215528	A1	20031120
APPLICATION INFO.:	US 2003-384499	A1	20030306 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-42039, filed on 25 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-842547, filed on 26 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362620P	20020307 (60)
	US 2002-362969P	20020306 (60)
	US 2001-277469P	20010321 (60)
	US 2000-199757P	20000426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	5245	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 22 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2003:226433 USPATFULL  
TITLE: Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment  
INVENTOR(S): Berthelette, Carl, Ste-Dorothee Laval, CANADA  
Lachance, Nicolas, Pierrefonds, CANADA  
Li, Lianhai, Pierrefonds, CANADA  
Sturino, Claudio, Beaconsfield, CANADA  
Wang, Zhaoyin, Kirkland, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158246	A1	20030821
APPLICATION INFO.:	US 2003-348403	A1	20030121 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-351384P	20020124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

## STN Columbus

LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fluoro substituted cycloalkanoindole derivatives are antagonists of  
prostaglandins, and as such are useful for the treatment of  
prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 23 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2002:152673 USPATFULL  
TITLE: Cyclopentanoindoles, compositions containing such  
compounds and methods of treatment  
INVENTOR(S): Labelle, Marc, Burlingame, CA, United States  
Sturino, Claudio, Dorval, CANADA  
Roy, Bruno, Ile Bizard, CANADA  
Berthelette, Carl, Ste-Dorothee Laval, CANADA  
Boyd, Michael, Montreal, CANADA  
Lachance, Nicolas, Pierrefonds, CANADA  
Scheigetz, John, Dollard des Ormeaux, CANADA  
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Kirkland, CANADA (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410583	B1	20020625
APPLICATION INFO.:	US 2001-909636		20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220683P	20000725 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
LEGAL REPRESENTATIVE:	Yang, Mollie M., Rose, David L.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1802	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted cyclopentanoindole derivatives are antagonists of  
prostaglandins, and as such are useful for the treatment of  
prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 24 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2001:235276 USPATFULL  
TITLE: Synergistic combination of PDE inhibitors and adenylate  
cyclase agonists or guanyl cyclase agonists  
INVENTOR(S): Schudt, Christian, Constance, Germany, Federal Republic  
of  
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance,  
Germany, Federal Republic of (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

## STN Columbus

PATENT INFORMATION: US 6333354 B1 20011225  
WO 9837894 19980903  
APPLICATION INFO.: US 1999-367850 19990827 (9)  
WO 1998-EP1047 19980224  
19990827 PCT 371 date  
19990827 PCT 102(e) date

NUMBER DATE  
-----  
PRIORITY INFORMATION: DE 1997-19708049 19970228  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Krass, Frederick  
ASSISTANT EXAMINER: Jagoe, Donna  
LEGAL REPRESENTATIVE: Jacobson Holman, PLLC  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 1  
LINE COUNT: 255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 24

L15 ANSWER 24 OF 24 USPATFULL on STN

DETD . . . DH-6471, SKF-94120, MOTAPIZONE, LIXAZINONE, INDOLIDAN, OLPRINONE, ATIZORAM, KS-506-G, DIPAMFYLLINE, BMY-43351, ATIZORAM, AROFYLLINE, FILAMINAST, PDB-093, UCB-29646, CDP-840, SKF-107806, PICLAMILAST, RS-17597, RS-25344-000, **SB-207499**, TIBENELAST, SB-210667, SB-211572, SB-211600, SB-212066, SB-212179 and GW-3600, CDP-840, in particular MOPIDAMOL, ANAGRELIDE, IBUDILAST, AMRINONE, PIMOBENDAN, CILOSTAZOL, QUAZINONE and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide.

DETD . . . by the combination according to the invention and the obstructions known as "irreversible" in vessel and bronchi can be reduced), **retinopathy**, nephropathy, diabetic angiopathy, edema formation and inflammations (the transpulmonary lymphocyte kinetics and the granulocyte influx) can be effectively prevented.

=> d ibib abs 16-19

L15 ANSWER 16 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2004:70711 USPATFULL  
TITLE: PDE IV inhibitors to treat angiogenesis  
INVENTOR(S): Gamache, Daniel A., Arlington, TX, UNITED STATES  
Bingaman, David P., Fort Worth, TX, UNITED STATES  
Kapin, Michael A., Arlington, TX, UNITED STATES

NUMBER KIND DATE  
-----

## STN Columbus

PATENT INFORMATION: US 2004053939 A1 20040318  
APPLICATION INFO.: US 2003-660152 A1 20030911 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-411001P	20020916 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Teresa J. Schultz, 6201 South Freeway, Mail Code Q-148, Fort Worth, TX, 76134-2099	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
LINE COUNT:	218	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Selective PDE-IV inhibitors are useful for preventing and treating angiogenic/edema related diseases and disorders.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 17 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2004:31859 USPATFULL  
TITLE: Spirobarbituric acid derivatives useful as inhibitors  
of matrix metalloproteases  
INVENTOR(S): Pitts, William J., Newtown, PA, UNITED STATES  
Kim, Soong-Hoon, Titusville, NJ, UNITED STATES  
Barbosa, Joseph, Lambertville, NJ, UNITED STATES  
Vaccaro, Wayne, Yardley, PA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2004024001	A1	20040205
APPLICATION INFO.:	US 2003-423788	A1	20030425 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-375336P	20020425 (60)
	US 2002-428355P	20021122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1845	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compound having the formula (I), ##STR1##	

wherein A, B and D are O or S; R1a and R1b are H,  
C1-4alkyl, C2-4alkenyl, or C2-4alkynyl; X is  
--NR2--, --S--, --S(.dbd.O)--, or --S(O)2--; G1, G2  
and G3 are together or separately selected from hetero, carbonyl,  
alkylene, and alkenylene groups and G4 is optionally substituted  
methylene; R2 is Q-Ar, wherein Q is a linker and Ar is substituted  
or substituted aryl or heteroaryl; and z is 0 or 1, are useful as  
inhibitors of MMPs, particularly MMP-13, aggrecanase, and/or TACE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 18 OF 24 USPATFULL on STN

## STN Columbus

Full Text

ACCESSION NUMBER: 2004:19478 USPATFULL  
TITLE: Combination therapy for the treatment of diseases  
involving inflammatory components  
INVENTOR(S): Krause, James E., Madison, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014782	A1	20040122
APPLICATION INFO.:	US 2003-401113	A1	20030327 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-368925P	20020329 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Leslie-Anne Horvath, Neurogen Corporation, Patent Department, 35 NE Industrial Road, Branford, CT, 06405	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9573	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio- and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 19 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2004:4504 USPATFULL  
TITLE: Tumor necrosis factor receptor 2  
INVENTOR(S): Stanton, Jr., Vincent P., Belmont, MA, United States  
PATENT ASSIGNEE(S): Nuvelo, Inc., Sunnyvale, CA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673908	B1	20040106
APPLICATION INFO.:	US 2001-968455		20011001 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-649035, filed on 25 Aug 2000 Continuation-in-part of Ser. No. US 2000-590749, filed on 8 Jun 2000, now abandoned Continuation-in-part of Ser. No. US 2000-495780, filed on 1 Feb 2000, now abandoned Continuation-in-part of Ser. No. US 2000-492712, filed on 27 Jan 2000, now abandoned Continuation-in-part of Ser. No. WO 2000-US1392, filed on 20 Jan 2000 Continuation-in-part of Ser. No. US 968455 Continuation-in-part of Ser. No. US 1999-451252, filed on 29 Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-427835, filed on 26 Oct 1999, now abandoned Continuation-in-part of		

STN Columbus

Ser. No. US 1999-414330, filed on 6 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-389993, filed on 3 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 1999-370841, filed on 9 Aug 1999, now abandoned Continuation-in-part of Ser. No. US 1999-300747, filed on 26 Apr 1999, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131334P	19990426 (60)
	US 1999-131191P	19990426 (60)
	US 1999-121047P	19990222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Benzion, Gary	
ASSISTANT EXAMINER:	Chakrabarti, Arun Kr.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	17463	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 19

L15 ANSWER 19 OF 24 USPATFULL on STN

SUMM . . . and the following is a list of the progressive complications that are associated with the unregulated carbohydrate balance in tissues: **retinopathy** leading to blindness, nephropathy (diabetic nephropathy is the leading cause of end-stage renal disease), coronary and cardiovascular disease, neuropathy (severe. . .

DETD . . . (methylene)tetrakis(phos

EDTMP; samarium phonato]](8)-

EDTMP; CYT 424; N,N',OP,OP', OP'',OP''']-

QUADRAMET samarate(5-)-153Sm

AE 941; NEOVASTAT; unspecified angiogenesis inhibitor; cancer; psoriasis;

NEORETNA; NSAID rheumatoid arthritis;

PSOVASCAR; eye disease;

ARTHROVAS **retinopathy**

FR 111142; WF 2015A 4,5-dihydroxy-2- angiogenesis inhibitor; cancer; rheumatoid hexenoic acid 5- NSAID arthritis; **retinopathy**

methoxy-4-[2-methyl-3-

(3-methyl-2-

butenyl)oxiranyl]-1-

oxaspiro[2.5]oct-6-yl

ester

troponin I; cartilage unspecified angiogenesis inhibitor; cancer; rheumatoid

derived inhibitor NSAID; arthritis; eye disease

biotechnology

MHC II peptidomimetic,. . . radical scavenging unspecified estrogen; free

STN Columbus

radical osteoporosis; arthritis;  
 estrogens, Jenapharm scavenger; NSAID neurological  
 TBC 2573 unspecified FGF antagonist; NSAID restenosis; rheumatoid  
 arthritis; **retinopathy**  
 CGP 39565 unspecified free radical scavenger; rheumatoid arthritis;  
 DMARD; NSAID arthritis  
 superoxide dismutase unspecified free radical scavenger; ischemia; arthritis  
 B, manganese complex, NSAID  
 Mn-SOD-B  
 free. . .  
 DETD . . . 1228 phosphoric acid phospholipase inhibitor; rheumatoid  
 arthritis  
 mono[2- NSAID  
 [(decylsulfonyl) amino]  
 octyl) mono[2-  
 (phenylmethoxy) ethyl]  
 ester  
 verteporfin; trans-18-ethenyl-4,4a- photosensitizer; NSAID cancer; psoriasis;  
 benzoporphyrin dihydro-3,4- arthritis; **retinopathy**  
 derivative; BPD-MA; CL bis(methoxycarbonyl)-  
 318952; BPDR; 4a,8,14,19-tetramethyl-  
 VISUDYNE 23H,25H-  
 benzo[b]porphine-9,13-  
 dipropanoic acid  
 monomethyl ester  
 polyclonal antibody, unspecified polyclonal antibody; rheumatoid arthritis;  
 tumor necrosis factor immunoglobulin;. . .  
 DETD . . . inhibitor; phospho-  
 diesterase IV inhibitor;  
 bronchodilator  
 piclamilast; RP 73401; 3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-  
 phosphodiesterase asthma; arthritis  
 RPR 73401 4-methoxybenzamide inhibitor; phospho-  
 diesterase IV inhibitor;  
 bronchodilator; NSAID  
**SB 207499; ARIFLO** cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxy-  
 phosphodiesterase asthma; pulmonary  
 phenyl]cyclohexanecarboxylic acid inhibitor; phospho- obstructive disease  
 diesterase IV inhibitor;  
 bronchodilator; NSAID  
 D 4418 N-(3,5-dichloro-4-pyridinyl)-8-methoxy-5- phosphodiesterase asthma  
 quinolinecarboxamide. . .  
 DETD . . . lipoxygenase inhibitor; inflammation; psoriasis  
 6,8,9,10- NSAID  
 tetrahydrobenzo[b] [1,8]  
 naphthyridin-5(7H)-one  
 AE 941; NEOVASTAT; unspecified angiogenesis inhibitor; cancer; psoriasis;  
 NEORETNA; NSAID rheumatoid arthritis; eye  
 PSOVASCAR; disease; **retinopathy**  
 ARTHROVAS  
 glycopine; N2- [N-[N-acetyl-4-O-[2- antibiotic; vaccine psoriasis; cancer;  
 glucosaminylmuramyl (acetyl amino)-2-deoxy- adjuvant; leukopenia; septic  
 dipeptide; GMDP; beta-D- immunostimulant; shock; infectious  
 LICOPID; LIKOPID glucopyranosyl]muramoyl]- glycopeptide disease; eye disease  
 . . . emphysema;  
 proteinase inhibitor psoriasis  
 efomycines unspecified Endothelium mediated psoriasis  
 antiadhesive properties  
 psoriasis enzyme unspecified enzyme psoriasis  
 therapy

STN Columbus

fibroblast growth factor unspecified FGF antagonist; cancer; **retinopathy**;  
antagonist angiogenesis inhibitor psoriasis  
free radical scavengers unspecified free radical scavenger; neurodegeneration;  
NSAID arthritis; reperfusion  
injury; psoriasis; stroke  
SLH 301 unspecified free radical. . . unspecified photosensitizer;  
psoriasis; skin disease;  
photodynamic therapy; contrast medium endometriosis; cancer;  
5-ALA PDT; LEVULAN diagnosis  
verteporfin; trans-18-ethenyl-4,4a- photosensitizer; NSAID cancer; psoriasis;  
benzoporphyrin dihydro-3,4- arthritis; **retinopathy**  
derivative; BPD-MA; CL bis(methoxycarbonyl)-  
318952; BPDR; 4a,8,14,19-tetramethyl-  
VISUDYNE 23H,25H-  
benzo[b]porphine-9,13-  
dipropionic acid  
monomethyl ester  
diethylhomospermine; N,N'-bis[4- polyamine analogue diarrhea; hypertension;  
DEHOP; DE 444 (ethylamino)butyl]-1,4- cancer;. . .  
DETD . . . antagonist psoriasis; cancer  
ALRT 1109 unspecified retinoid antagonist; psoriasis  
RAR antagonist  
lanreotide; BIM 23014; 3-(2-naphthalenyl)-D- somatostatin analogue cancer;  
acromegaly;  
DC 13116; BIM alanyl-L-cysteinyl-L- **retinopathy**; diabetes;  
23014C; BN 52030; tyrosyl-D-tryptophyl-L- psoriasis; restenosis  
SOMATULINE; lysyl-L-valyl-L-cysteinyl-  
ANGIOPEPTIN; L-threoninamide cyclic  
DERMOPEPTIN; (2,7)-disulfide  
IPSTYL  
octreotide; octreotide [R-(R\*,R\*)]-D- somatostatin analogue; Alzheimer disease;  
acetate; SMS; SMS phenylalanyl-L- analgesic. . .  
DETD . . . (E)-O- phosphodiesterase IV  
(aminocarbonyl)oxime inhibitor; bronchodilator  
piclamilast; RP 73401; 3-cyclopentyloxy-N-(3,5- phosphodiesterase asthma;  
arthritis  
RPR 73401 dichloropyridin-4-yl)-4- inhibitor;  
methoxybenzamide phosphodiesterase IV  
inhibitor; bronchodilator  
NSAID  
**SB 207499**; **ARIFLO** cis-4-cyano-4-[3- phosphodiesterase asthma; pulmonary  
(cyclopentyloxy)-4- inhibitor; obstructive disease  
methoxyphenyl]cyclo- phosphodiesterase IV  
hexanecarboxylic acid inhibitor; bronchodilator  
NSAID  
D 4418 Unspecified phosphodiesterase asthma  
. . .

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

43.32

107.70

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:51:28 ON 09 FEB 2005

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'MEDLINE, HCAPLUS, BIOSIS, USPATFULL, WPIDS'

AT 16:52:44 ON 09 FEB 2005

STN Columbus

FILE 'MEDLINE' ENTERED AT 16:52:44 ON 09 FEB 2005  
 FILE 'HCAPLUS' ENTERED AT 16:52:44 ON 09 FEB 2005  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)  
 FILE 'BIOSIS' ENTERED AT 16:52:44 ON 09 FEB 2005  
 Copyright (c) 2005 The Thomson Corporation.  
 FILE 'USPATFULL' ENTERED AT 16:52:44 ON 09 FEB 2005  
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)  
 FILE 'WPIDS' ENTERED AT 16:52:44 ON 09 FEB 2005  
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.32	107.70

=> d his

(FILE 'HOME' ENTERED AT 16:37:18 ON 09 FEB 2005)

FILE 'REGISTRY' ENTERED AT 16:39:37 ON 09 FEB 2005

FILE 'CAPLUS' ENTERED AT 16:39:50 ON 09 FEB 2005

L1 210 S PDE 4  
 L2 7455 S MACULAR OR RETINOPATHY  
 L3 2 S L1 AND L2  
 L4 2 S WO2001034606/PN

FILE 'REGISTRY' ENTERED AT 16:43:41 ON 09 FEB 2005

L5 1 S V-11294A  
 L6 1 S D-4418  
 L7 1 S BRL-61063  
 L8 1 S SB-207499  
 SEL RN NAME L5  
 SEL RN NAME L6  
 SEL RN NAME L7  
 SEL RN NAME L8

FILE 'MEDLINE, HCAPLUS, BIOSIS, USPATFULL, WPIDS' ENTERED AT 16:45:25 ON 09 FEB 2005

L9 125 S E1-2  
 L10 106 S E3-4  
 L11 182 S E5-8  
 L12 603 S E9-14  
 L13 72967 S MACULAR DEGENERAT? OR RETINOPATHY  
 L14 24 S L12 AND L13  
 L15 24 DUP REM L14 (0 DUPLICATES REMOVED)

=> s angiogen?

L16 106020 ANGIOGEN?

=> s angiogenesis or angiogenic

L17 104600 ANGIOGENESIS OR ANGIOGENIC

=> s l17 and l12

L18 33 L17 AND L12

=> dup rem l18

PROCESSING COMPLETED FOR L18

L19 33 DUP REM L18 (0 DUPLICATES REMOVED)

=> d ibib abs 30-33

## STN Columbus

L19 ANSWER 30 OF 33 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2003:134643 USPATFULL  
TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same  
INVENTOR(S): Yu, Guixue, Lawrenceville, NJ, UNITED STATES  
Macor, John, Guilford, CT, UNITED STATES  
Herpin, Timothy, Princeton, NJ, UNITED STATES  
Lawrence, R. Michael, Yardley, PA, UNITED STATES  
Morton, George C., Collegeville, PA, UNITED STATES  
Ruel, Rejean, Saint-Lambert, CANADA  
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES  
Ruediger, Edward H., Greenfield Park, CANADA  
Thibault, Carl, Mascouche, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092732	A1	20030515
APPLICATION INFO.:	US 2002-90582	A1	20020304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-273206P	20010302 (60)
	US 2001-273291P	20010302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2878	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, ##STR1##

in which E is

X is N or CH, W is --NR16R17, --NR16C(.dbd.O)R22, --NR16CO2R22, --OR23, or a heteroaryl or heterocyclo group as defined in the specification, and R1 through R12, R16, R17, R22, R23, x, y, and z are as defined in the specification, are useful as modulators of melanocortin receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 31 OF 33 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2003:100059 USPATFULL  
TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders  
INVENTOR(S): Macor, John E., Guilford, CT, UNITED STATES  
Carlson, Kenneth E., West Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069169	A1	20030410

## STN Columbus

APPLICATION INFO.: US 2002-90258 A1 20020304 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-273206P	20010302 (60)
	US 2001-273291P	20010302 (60)
	US 2001-289719P	20010509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2497	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatitis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 32 OF 33 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2002:254380 USPATFULL

TITLE: Substituted  $\gamma$ -phenyl- $\Delta$ -lactones and analogs thereof and uses related thereto

INVENTOR(S): Shen, Yaping, Port Coquitlam, CANADA  
Burgoyne, David L., Delta, CANADA  
Lauener, Ronald W., Westminister, CANADA  
Zhou, Yuanlin, Richmond, CANADA  
Rebstein, Patrick J., Vancouver, CANADA  
Abraham, Samuel D. M., Vancouver, CANADA

PATENT ASSIGNEE(S): Inflazyme Pharmaceuticals Ltd., Richmond, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 6458829	B1	20021001
	WO 2000014083		20000316
APPLICATION INFO.:	US 2001-786949		20010511 (9)
	WO 1999-CA819		19990909
			20010511 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 1999-149517P	19990817 (60)
	US 1999-121507P	19990223 (60)
	US 1998-99637P	19980909 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Owens, Amelia	

## STN Columbus

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC  
NUMBER OF CLAIMS: 63  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 5553

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB  $\gamma$ -Phenyl-substituted  $\Delta$ -lactones and analogs thereof,  
including lactams, are disclosed. They may be formulated into  
pharmaceutical compositions, and/or used in the treatment or prevention  
of inflammation or other conditions or disease states.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 33 OF 33 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2002:152673 USPATFULL  
TITLE: Cyclopentanoindoles, compositions containing such  
compounds and methods of treatment  
INVENTOR(S): Labelle, Marc, Burlingame, CA, United States  
Sturino, Claudio, Dorval, CANADA  
Roy, Bruno, Ile Bizard, CANADA  
Berthelette, Carl, Ste-Dorothee Laval, CANADA  
Boyd, Michael, Montreal, CANADA  
Lachance, Nicolas, Pierrefonds, CANADA  
Scheigetz, John, Dollard des Ormeaux, CANADA  
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Kirkland, CANADA (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410583	B1	20020625
APPLICATION INFO.:	US 2001-909636		20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220683P	20000725 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
LEGAL REPRESENTATIVE:	Yang, Mollie M., Rose, David L.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1802	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted cyclopentanoindole derivatives are antagonists of  
prostaglandins, and as such are useful for the treatment of  
prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 117 and 111  
L20 30 L17 AND L11

=> s 19-12  
L21 782 (L9 OR L10 OR L11 OR L12)

=> s 117 and 121  
L22 63 L17 AND L21

## STN Columbus

=> s l13 and l21

L23 32 L13 AND L21

=> dup rem l23

PROCESSING COMPLETED FOR L23

L24 32 DUP REM L23 (0 DUPLICATES REMOVED)

=> d ibib abs 29-32

L24 ANSWER 29 OF 32 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2003:207932 USPATFULL  
TITLE: N-alkyl-adamantyl triazinyl benzamide derivatives  
INVENTOR(S): Duplantier, Allen J., Ledyard, CT, UNITED STATES  
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144293	A1	20030731
APPLICATION INFO.:	US 2002-292886	A1	20021112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336892P	20011112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2342	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formula I ##STR1##

and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 30 OF 32 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2002:288136 USPATFULL  
TITLE: 1,4-dihydropyridine compounds as bradykinin antagonists  
INVENTOR(S): Kawamura, Mitsuhiro, UNITED STATES  
Kawai, Makoto, UNITED STATES  
Shishido, Yuji, UNITED STATES  
Kato, Tomoki, UNITED STATES  
Katsu, Yasuhiro, UNITED STATES  
Ikeda, Takafumi, UNITED STATES  
Murase, Noriaki, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002161006	A1	20021031

## STN Columbus

APPLICATION INFO.: US 6653313 B2 20031125  
US 2001-903157 A1 20010711 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-224558P	20000810 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4634	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to compounds of the formula ##STR1##	

wherein each A is independently halo; Y is --(CH<sub>2</sub>)<sub>m</sub>--,  
--C(O)-- or --S(O)--; R<sub>1</sub> and R<sub>2</sub> are independently C<sub>1</sub>-4  
alkyl; R<sub>3</sub> is substituted azacycloalkyl etc.; R<sub>4</sub> is phenyl  
substituted at the 2-position with a substituent selected from  
substituted C<sub>1</sub>-7 alkyl, substituted C<sub>1</sub>-7 alkoxy, amine, etc;  
R<sub>5</sub> is hydrogen or C<sub>1</sub>-4 alkyl; m is 0, 1 or 2; and n is 0, 1,  
2, 3, 4 or 5. The present invention also relates to pharmaceutical  
compositions containing such compounds and to the use of such compounds  
in the treatment and prevention of inflammation, asthma, allergic  
rhinitis, pain and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 31 OF 32 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2002:152673 USPATFULL  
TITLE: Cyclopentanoindoles, compositions containing such  
compounds and methods of treatment  
INVENTOR(S): Labelle, Marc, Burlingame, CA, United States  
Sturino, Claudio, Dorval, CANADA  
Roy, Bruno, Ile Bizard, CANADA  
Berthelette, Carl, Ste-Dorothee Laval, CANADA  
Boyd, Michael, Montreal, CANADA  
Lachance, Nicolas, Pierrefonds, CANADA  
Scheigetz, John, Dollard des Ormeaux, CANADA  
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Kirkland, CANADA (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410583	B1	20020625
APPLICATION INFO.:	US 2001-909636		20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220683P	20000725 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
LEGAL REPRESENTATIVE:	Yang, Mollie M., Rose, David L.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1802	

## STN Columbus

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 32 OF 32 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2001:235276 USPATFULL  
TITLE: Synergistic combination of PDE inhibitors and adenylyate cyclase agonists or guanyl cyclase agonists  
INVENTOR(S): Schudt, Christian, Constance, Germany, Federal Republic of  
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333354	B1	20011225
	WO 9837894		19980903
APPLICATION INFO.:	US 1999-367850		19990827 (9)
	WO 1998-EP1047		19980224
			19990827 PCT 371 date
			19990827 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19708049	19970228
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Krass, Frederick	
ASSISTANT EXAMINER:	Jagoe, Donna	
LEGAL REPRESENTATIVE:	Jacobson Holman, PLLC	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	255	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylyate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	98.05	162.43

FILE 'STNGUIDE' ENTERED AT 17:05:21 ON 09 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 4, 2005 (20050204/UP).

=>

